Jubilant Pharmova
1,070.40
+5.60(+0.53%)
Market Cap₹17,049.45 Cr
PE Ratio34.90
IndustryHealthcare
Company Performance:
1D+0.53%
1M-4.35%
6M+19.48%
1Y+14.15%
5Y+37.41%
View Company Insightsright
More news about Jubilant Pharmova
13Jun 25
Jubilant Pharmova Shares See Massive Block Trade Worth Rs. 512 Crore on NSE
A large block trade of approximately 4,804,883 shares of Jubilant Pharmova Ltd. occurred on the National Stock Exchange (NSE). The transaction, valued at Rs. 511.96 crore, was executed at Rs. 1,065.50 per share. This significant trade indicates potential changes in the company's ownership structure and provides a reference point for market valuation. Jubilant Pharmova, a key player in the Indian pharmaceutical sector, operates in contract research and development services, proprietary novel drugs, and radiopharmaceuticals.
13Jun 25
Jubilant Pharmova to Transfer API Business to Wholly Owned Subsidiary
Jubilant Pharmova Limited's board has approved the sale and transfer of its Active Pharmaceutical Ingredients (API) business to Jubilant Biosys Limited, a wholly owned subsidiary. The transfer will be executed on a slump sale basis, involving the entire business unit as a going concern. This strategic move aims to streamline operations, enhance focus on the API segment, and potentially drive growth opportunities.
12Jun 25
Jubilant Pharmova to Transfer API Division to Wholly Owned Subsidiary
Jubilant Pharmova's board has approved the transfer of its Active Pharmaceutical Ingredients (API) division to its wholly owned subsidiary, Jubilant Biosys Limited. The transfer will be executed as a slump sale, with the API division reporting a turnover of ₹609.00 crore, representing 8.35% of the company's consolidated revenue. The transfer is expected to be completed by September 1, 2025, with consideration based on the book value of assets and liabilities of the API division.
20Mar 25
Jubilant Pharmova Expands Global R&D Footprint with Strategic Acquisition in France
Jubilant Pharmova's subsidiary, Jubilant Biosys Innovative Research Services Pte Limited, has acquired an 80% stake in JASMIN, now renamed Jubilant Biosys France. This new entity has acquired Pierre Fabre's R&D Centre in Saint Julien, France. Pierre Fabre SA retains a 20% stake in Jubilant Biosys France. The deal, closed on March 19, 2025, enhances Jubilant Pharmova's research infrastructure in Europe, potentially accelerating drug discovery and development processes.
13Mar 25
Jubilant Pharmova's US Subsidiary Clears USFDA Inspection with VAI Status
Jubilant Pharmova's subsidiary, Jubilant Cadista Pharmaceuticals Inc., received an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the USFDA for its Salisbury, Maryland facility. The inspection was conducted in January 2025, and the company was notified on March 11, 2025. Despite this positive outcome, the facility is not expected to manufacture any products in the future, as its operations have been closed, a decision previously announced in April 2024.
12Mar 25
Jubilant Pharmova's US Subsidiary Clears FDA Inspection with VAI Status
Jubilant Cadista Pharmaceuticals Inc., a US subsidiary of Jubilant Pharmova, received an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the FDA for its Salisbury, Maryland facility in January 2025. The inspection concluded satisfactorily, allowing continued operations without major regulatory concerns. However, the company has previously announced the closure of manufacturing operations at this facility, as disclosed in April 2024.
Jubilant Pharmova
1,070.40
+5.60
(+0.53%)
1 Year Returns:+14.15%
Industry Peers
Sun Pharmaceutical
1,593.60
(+0.71%)
Divis Laboratories
6,009.00
(-2.03%)
Cipla
1,553.40
(-1.55%)
Torrent Pharmaceuticals
3,579.10
(-0.56%)
Dr Reddys Laboratories
1,268.10
(+1.21%)
Mankind Pharma
2,550.60
(-0.71%)
Zydus Life Science
1,013.85
(+0.19%)
Lupin
1,943.90
(+0.24%)
Abbott
31,150.00
(-3.19%)
Alkem Laboratories
5,333.50
(+0.60%)